Benchmark Reaffirms “Speculative Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “speculative buy” rating reiterated by equities researchers at Benchmark in a report issued on Tuesday,Benzinga reports. They presently have a $1.00 price target on the stock, down from their prior price target of $10.00. Benchmark’s price target would indicate a potential upside of 66.39% from the company’s previous close.

A number of other analysts have also issued reports on the company. Wall Street Zen lowered Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. BTIG Research decreased their target price on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday. UBS Group reiterated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.43.

Humacyte Trading Up 4.6%

Shares of NASDAQ HUMA traded up $0.03 during mid-day trading on Tuesday, reaching $0.60. The company had a trading volume of 3,044,514 shares, compared to its average volume of 6,874,543. The stock has a market cap of $112.55 million, a price-to-earnings ratio of -3.07 and a beta of 1.89. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.93. The business’s 50-day moving average is $1.03 and its 200-day moving average is $1.27. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.35 million. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 808.20%. Equities analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently made changes to their positions in the business. Prudential Financial Inc. acquired a new stake in shares of Humacyte in the 2nd quarter worth $28,000. Financial Advisors Network Inc. acquired a new position in Humacyte during the 2nd quarter valued at about $28,000. Valeo Financial Advisors LLC acquired a new position in Humacyte during the 2nd quarter valued at about $32,000. Truist Financial Corp purchased a new stake in Humacyte in the third quarter valued at about $28,000. Finally, Cerity Partners LLC purchased a new stake in Humacyte in the second quarter valued at about $35,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.